目的 研究硼酸软膏联合重组人表皮生长因子凝胶治疗压疮的临床疗效。方法 选取2017年6月-2019年6月在连云港市第一人民医院治疗的120例压疮患者为研究对象，所有患者随机分为对照组和治疗组，每组各60例。对照组患者在伤口处给予重组人表皮生长因子凝胶，10 g/100 cm²，1次/d，外敷油纱条，然后再外敷干纱布固定。治疗组患者在对照组基础上给予硼酸软膏，取适量涂于患处，外敷油纱条，然后再外敷干纱布固定，1次/d。两组患者持续治疗14 d。观察两组的临床疗效，比较两组的临床症状缓解时间、血清炎性因子水平、视觉模拟评分法（VAS）评分。结果 治疗后，对照组和治疗组的总有效率分别为86.67%、95.00%，两组比较差异有统计学意义（P<0.05）。治疗后，治疗组患者创面愈合时间、渗液消失时间、新生肉芽组织生长时间均显著短于对照组，两组比较差异有统计学意义（P<0.05）。治疗后，两组患者白细胞介素-1β（IL-1β）、白细胞介素-6（IL-6）、肿瘤坏死因子-α（TNF-α）水平均显著降低，同组治疗前后比较差异有统计学意义（P<0.05）；并且治疗组患者血清炎性因子水平明显低于对照组，两组比较差异有统计学意义（P<0.05）。治疗后，两组患者VAS评分显著降低，同组治疗前后比较差异有统计学意义（P<0.05）；且治疗组患者VAS评分明显低于对照组，两组比较差异有统计学意义（P<0.05）。结论 硼酸软膏联合重组人表皮生长因子凝胶治疗压疮具有较好的治疗效果，可改善临床症状，促进伤口愈合，调节血清炎性因子水平，具有一定的临床推广应用价值。

Objective To study the effect of Boric Acid Ointment combined with Recombinant Human Epidermal Growth Factor Gel in treatment of pressure ulcers. Methods Patients (120 cases) with pressure ulcers in the First People's Hospital of Lianyungang from June 2017 to June 2015 were randomly divided into control and treatment groups, and each group had 60 cases. Patients in the control group were given Recombinant Human Epidermal Growth Factor Gel (Yeast), 10 g/100 cm², once daily, applied oil gauze and then dry gauze for fixation. Patients in the treatment group were given Boric Acid Ointment on the basis of the control group, applied appropriate amount to the affected area, applied oil gauze and then dry gauze for fixation, once daily. Patients in two groups were treated for 14 d. After treatment, the clinical efficacies were evaluated, and clinical symptom remission time, serum levels of inflammatory factors, and VAS scores in two groups were compared. Results After treatment, the clinical efficacies in the control and treatment groups were 86.67% and 95.00%, respectively, and there was difference between two groups (P<0.05). After treatment, wound healing time, exudate disappearance time, and new granulation tissue growth time in the treatment group were significantly shorter than those in the control group, and there was difference between two groups (P<0.05). After treatment, the levels of IL-1β, IL-6 and TNF-α in two groups were significantly decreased, and the difference was statistically significant in the same group (P<0.05). And the serum levels of inflammatory factors in the treatment group were significantly lower than those in the control group, with significant difference between two groups (P<0.05). After treatment, VAS scores in two groups were significantly decreased, and the difference was statistically significant in the same group (P<0.05). And the VAS score in the treatment group was significantly lower than those in the control group, with significant difference between two groups (P<0.05). Conclusion Boric Acid Ointment combined with Recombinant Human Epidermal Growth Factor Gel has clinical curative effect in treatment of pressure ulcers, can improve clinical symptoms, promote wound healing, and regulate the level of serum inflammatory factors, which has a certain clinical application value.